Posted on 16/12/2009 in Scientific Life Technologies has announced the completion of its acquisition of BioTrove.
In a statement, the scientific organisation, which did not disclose the amount it paid to purchase the company, said that it does not expect the move to have a material effect on its financials for the 2009 fiscal year.
Life Technologies noted that BioTrove's primary technology is the OpenArray platform, which is a high-throughput genotyping analysis and gene expression system.
It is based on a flexible array format, meaning that users are able to carry out more than 3,000 PCR genotyping or qPCR gene expression assays at once.
Life Technologies announced that it signed a definitive agreement to purchase BioTrove on November 10th.
Speaking at the time, Greg Lucier, chairman and chief executive officer of the company, said that BioTrove's technology is an "important addition" to its PCR portfolio.
"This acquisition and other enhancements recently made to our PCR offerings enable us to remain the leader in this space and exemplify how Life Technologies is setting new technology standards," he added.Other news stories from 16/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
